20 Jul Tiber Biotech
Maddalena Pacelli, CEO and Founder
Oct. 5 | 9:00am | FLW Ballroom G
Rome, Italy
(Private)
Tiber Biotech is developing personalized monoclonal antibody therapies designed for individual patients, enabling unprecedented selectivity in the elimination of disease-causing lymphocytes whitout the off-target effects that limit today’s therapies. Its proprietary SAMBA platform combines bioinformatics and AI to identify patient-specific immune cell fingerprints and generate highly selective antibodies that spare healthy immune cells, creating a new therapeutic approach for blood cancers, autoimmune diseases, and transplant rejection. The company’s core IP lies in a scalable manufacturing platform for personalized N-of-1 therapies. By addressing process consistency rather than product consistency, Tiber Biotech is aligned with the evolving regulatory framework for individualized medicines and is pioneering the world’s first commercial platform for N-of-1 biologics.